Plans to Expand Sales in Neighboring Countries

Dong-A ST announced on October 12 that it had launched Dabecron, a biosimilar treatment for anemia whose active ingredient is darbepoetin alfa, in the United Arab Emirates (UAE).

Product image of Dabecron (DA-3880), a darbepoetin alfa biosimilar developed by Dong-A ST. Dong-A ST

Product image of Dabecron (DA-3880), a darbepoetin alfa biosimilar developed by Dong-A ST. Dong-A ST

View original image

The launch marks the first commercialization of Dabecron (project code DA-3880) in the MENA region (the Middle East and North Africa). Dong-A ST plans to use this as a foothold to expand sales in neighboring countries.


In November 2024, Dong-A ST signed a licensing agreement with UAE pharmaceutical company Julphar for Dabecron in 18 countries across the MENA region. Under the agreement, Julphar is responsible for obtaining marketing approvals and commercializing the product in the region. Julphar obtained marketing approval for Dabecron in the UAE in June 2026 and has since completed its local launch.


Dabecron is a biosimilar of darbepoetin alfa, a second-generation treatment for anemia. It is used to treat anemia in patients with chronic kidney disease and anemia caused by cancer chemotherapy.


In 2014, Dong-A ST signed a technology-export agreement with Japan's Sanwa Kagaku Kenkyusho (SKK) for the development and sale of Dabecron in Japan. After obtaining manufacturing and marketing approval in Japan in 2019, the product has been sold under the name "Darbepoetin Alfa BS Injection Sanwa." Sales in Japan rose approximately 62%, from 16.5 billion won in 2024 to 26.7 billion won in 2025.


Dong-A ST is marketing or developing Dabecron as a Nesp biosimilar in Japan, the MENA region, and Türkiye. At the same time, it is pursuing development as an Aranesp biosimilar for major markets, including the United States and Europe.



A Dong-A ST official said, "The successful marketing approval and launch of Dabecron in the UAE have laid the groundwork for expanding into the MENA market. Through our partnership with Julphar, we will expand the number of countries where the product is sold and continue development without disruption to pursue entry into major global markets, including the United States and Europe."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing